Contacts
Info
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is...
show more-
FCR vs. BR - Is One Better?
26 AUG 2016 · Jennifer Brown, MD, discusses the choice in chemoimmunotherapy, FCR (fludarabine, cyclophosphamide and rituximab) vs BR. FCR has been the standard therapy for previously untreated fit patients with CLL under about the age of 70. While BR (bendamustine and rituximab), is a relatively newer therapy, which had been studied in a couple of phase two trials - smaller single arm trials and look to be promising. -
Basics of Small Cell Lung Cancer
23 AUG 2016 · Lung Cancer Video Library ASCO 2016 Rachel Sanborn Basics of Small Cell Lung Cancer -
Adjuvant Chemotherapy for Elderly and Frail Patients
23 AUG 2016 · Lung Cancer Video Library ASCO 2016 - Rachel Sanborn - Adjuvant Chemotherapy for Elderly and Frail Patients -
Rachel Sanborn - Adjuvant Chemotherapy for Early Stage NSCLC Patients, part 1
22 AUG 2016 · Lung Cancer Video Library - Rachel Sanborn - Adjuvant Chemotherapy for Early Stage NSCLC Patients, part 1 -
New Trials of Targeting Therapies to Treat Leptomeningeal Carcinomatosis
11 AUG 2016 · GRACE is happy to present the 8th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss new trials of targeting therapies used to treat leptomeningeal carcinomatosis. -
ASCO 2016 LC RT Vid 8 - Promising Early Results for Treatments
11 AUG 2016 · GRACE is happy to present the 8th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss promising early results for treatments targeting new mutations. -
Immuno-oncology Developments - Combinations and Use as First-Line Therapy
11 AUG 2016 · GRACE is happy to present the 6th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss Immuno-oncology developments - combinations and use as first-Line therapy. -
Does Current Evidence Support Favoring Proton-Beam Radiation
4 AUG 2016 · GRACE is happy to present the 6th video in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.  Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss whether current evidence supports favoring proton beam radiation. -
J-Alex Trial: Should Alecensa Replace Xalkori as First-Line ALK Therapy?
4 AUG 2016 · GRACE is happy to present the 5th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the J-Alex trial and whether Alecensa should replace Xalkori as First-Line ALK Therapy. -
Are There Less Toxic Alternatives to the Extreme Regimen
3 AUG 2016 · GRACE is happy to present the 9th video in our series ASCO 2016 Head and Neck Roundtable, Treating Head and Neck Cancer. Featuring Jared Weiss, MD, Joshua Bauml, MD, and Tanguy Seiwert, MD, this roundtable discussion, moderated by Dr. Weiss, highlights intriguing discussions regarding head and neck cancers from ASCO 2016. Drs. Weiss, Bauml and Seiwert discuss the topic of whether there are less toxic alternatives to the extreme regimen.
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is...
show moreInformation
Author | cancerGRACE |
Categories | Medicine , Science , Education |
Website | www.spreaker.com |
- |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company